NASDAQ: GLSIGreenwich Lifesciences Inc Stock
$11.27-0.41 (-3.51%)
Updated Sep 16, 2025
GLSI Price
$11.27
Fair Value Price
$0.31
Market Cap
$153.61M
52 Week Low
$8.06
52 Week High
$15.50
P/E
-8.29x
P/B
106.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.17
Operating Cash Flow
-$9M
Beta
0.58
Next Earnings
Nov 10, 2025
Ex-Dividend
N/A
Next Dividend
N/A
GLSI Overview
Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company developing novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Known as Norwell, Inc. until 2018, Greenwich LifeSciences was incorporated in 2006 and is headquartered in Stafford, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GLSI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GLSI
Ranked#303 of 479
Ranked#303 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.87 | A | |
| $34.98 | A | |
| $7.75 | A |
Be the first to know about important GLSI news, forecast changes, insider trades & much more!
GLSI News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GLSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GLSI ($11.27) is overvalued by 3,484.43% relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GLSI ($11.27) is not significantly undervalued (3,484.43%) relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GLSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GLSI due diligence checks available for Premium users.
Valuation
GLSI fair value
Fair Value of GLSI stock based on Discounted Cash Flow (DCF)
Price
$11.27
Fair Value
$0.31
Overvalued by
3,484.43%
GLSI ($11.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GLSI ($11.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GLSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GLSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.29x
Industry
-95.43x
Market
37.55x
GLSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
106.71x
Industry
4.68x
GLSI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GLSI's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.0M
Profit Margin
0%
GLSI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.1M
Liabilities
$1.7M
Debt to equity
1.17
GLSI's short-term assets ($3.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GLSI's short-term assets ($3.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GLSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GLSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$0.0
Financing
$2.6M
GLSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GLSI vs Biotech Stocks
Greenwich Lifesciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.